Market Price

12.13 

-0.35 -2.8%

as of Oct 20 '17 16:00

52 Week Range:

8.31 24.30


Stock Analyzer Tutorials

S2O Stock Analyzer - General Info

General Info


type: video (mp4); length: 3:30

Demonstrates how to use Stock Analyzer, shows how to analyze a stock and explains in detail "General Info" section of the Stock Analyzer result page.

S2O Stock Analyzer - Financial Statements

Financial Statements


type: video (mp4); length: 5:10

Explains information presented in the Financial Statements section of the S2O Stock Analyzer: financial statements charts, absolute values and growth rates.

S2O Stock Analyzer - Growth Grade and Financial Ratios

Growth Grade and Financial Ratios


type: video (mp4); length: 5:09

Demonstrates how to use Growth Grade & Financial Ratios section; shows the difference between historical and year-over-year Growth Grade on the real life example.

S2O Stock Analyzer - Value Price

Value Price


type: video (mp4); length: 6:03

Demonstrates how to use Value Price (intrinsic value) and the Graham Number, MOS (margin of safety) and IRT - Investment Recovery Time; explains 3 different projection models used to compute value price - pessimistic, moderate and optimistic.

S2O Stock Analyzer - Price Charts

Price Charts


type: video (mp4); length: 8:34

Demonstrates basic rules of how to read a candlestick chart, long and short term moving averages, stochastic, MACD and relative strength (RS) charts. Explains how bull or bear market condition is computed.

General Info

Valeant Pharmaceuticals International, Inc. operates as a pharmaceutical and medical device company worldwide. It operates in three segments: Bausch + Lomb/International, Branded Rx, and U.S. Diversified Products. The company offers Lotemax gel for the treatment of inflammation and pain following ocular surgery; Ocuvite, a lutein eye vitamin and mineral supplement; PreserVision, an antioxidant eye vitamin and mineral supplement; ReNu Multiplus products; Biotrue multi-purpose solution for healthy contact lens wear; Artelac to treat dry eyes; Boston, a cleansing solution for gas permeable contact lenses; and Bedoyecta, a vitamin B complex. It also provides SofLens daily disposable contact lenses; ophthalmic surgical products; PureVision, a silicone hydrogel; Biotrue ONEday daily disposable contact lenses; Bausch + Lomb Ultra, a silicone hydrogel replacement contact lens; and medical device systems. In addition, the company offers Xifaxan for the treatment of irritable bowel syndrome; Provenge for the treatment of prostate cancer; Uceris to get ulcerative colitis under control; Arestin, a subgingival sustained-release antibiotic; Jublia for the treatment of onychomycosis; Solodyn for the treatment of acne; Elidel to treat skin conditions; and Glumetza tablets to enhance glycemic control. Further, it provides Wellbutrin XL for the treatment of major depressive disorder; Isuprel injections; Xenazine for the treatment of chorea; Nitropress for the reduction of blood pressure of patients in hypertensive crises; Cuprimine to treat Wilson's disease; Zegerid to treat certain stomach and esophagus problems; Tobramycin and Dexamethasone ophthalmic suspension for steroid responsive inflammatory ocular conditions; and Latanoprost medicines to treat a type of glaucoma. The company was formerly known as Biovail Corporation and changed its name to Valeant Pharmaceuticals International, Inc. in September 2010. The company was founded in 1983 and is headquartered in Laval, Canada.

Financial Statements

The charts below show selected Annual and Quarterly Financial Data.

The purpose of these charts is to discover long and short term change dynamics. When numbers are growing year after year in the annual statements chart, the business become stronger and stronger and this is a good sign.

Quarterly Data Chart can be used to do a short term analysis. It makes sense to pay attention to the quarterly dynamics and do not wait for the next yearly statement. We should be alerted if we see that quarterly numbers are going down.

You can check "Annual Financial Statements" and "Quarterly Financial Statements" sections for exact numbers and growth rates.

Annual Statements

On a charts below the Line shows absolute values and the Bar chart shows Year-Over-Year Growth Rate for selected financial statement item. A consistent GROWTH is generally considered necessary to fund future growth from within a business.
NOTE: Growth Rate is not provided if either the latest period or the year-ago period contains a net loss. (source: WSJ Digest of Earnings)
TIP! move your mouse pointer over bar or a circle on any chart below to see details.

Financial Statements

Income Statement



 

Cash Flow Statement



 

Balance Sheet



 

Liquidity Ratios

Current Ratio


 

Current Ratio measures the ability to meet short term obligations. Generally accepted standard is 2 (current assets should be 2 times or 200% of current liabilities).

Quick Ratio


 

Measures immediate liquidity or the cash available to cover immediate liabilities. A safe margin would be at least 1 (100%).

Financial Leverage


 

Defined as total assets divided by total shareholders' equity. The higher the ratio, the more debt a company uses in its capital structure.

Profitability Ratios

ROA


 

Return on Assets (ROA) measures the income (profit) that is generated by the use of the assets of the business.

ROE


 

Return on Equity (ROE) is a measure of profitability that calculates how many dollars of profit a company generates with each dollar of shareholders equity. ROE is sometimes called "return on net worth."

ROIC


 

The Return on Invested Capital (ROIC) measure gives a sense of how well a company is using its money to generate returns. Some investors use this figure as a final evaluation to determine whether or not to invest in a company.

Annual Statements

Item Name Dec '06 Dec '07 Dec '08 Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16
Equity (BVPS) 7.92
8.06
7.59
8.56
16.24
13.10
12.23
14.86
15.32
18.49
11.98
growth rate 1.8% -5.8% 12.8% 89.7% -19.3% -6.6% 21.5% 3.1% 20.7% -35.2%
Earnings BIT 222.29
208.74
140.60
335.60
-236.26
-18.00
-394.23
1,545.70
2,025.00
1,408.00
-599.00
growth rate -6.1% -32.6% 138.7% -100.0% 0.0% 0.0% 100.0% 31.0% -30.5% -100.0%
Avg.PE 16.29
11.04
7.56
12.55
95.24
-137.50
89.83
73.96
17.86
17.86
growth rate -32.2% -31.5% 66.0% 175.5% -100.0% 100.0% -17.7% -75.9% 0.0%
ROA 9.35
9.88
11.74
9.56
-3.24
1.33
-0.75
-3.77
3.36
-0.77
-5.21
growth rate 5.7% 18.8% -18.6% -100.0% 100.0% -100.0% 0.0% 100.0% -100.0% 0.0%
ROE 15.31
15.14
16.00
13.81
-6.65
3.58
-3.00
-19.60
17.52
-5.20
-53.16
growth rate -1.1% 5.7% -13.7% -100.0% 100.0% -100.0% 0.0% 100.0% -100.0% 0.0%
ROIC 11.93
14.07
15.52
12.02
-2.61
4.20
1.85
-1.70
7.99
2.97
-1.72
growth rate 17.9% 10.3% -22.6% -100.0% 100.0% -56.0% -100.0% 100.0% -62.8% -100.0%
Cur. Ratio 2.58
1.92
1.84
1.36
1.47
1.47
1.52
1.55
1.54
1.04
1.41
growth rate -25.6% -4.2% -26.1% 8.1% 0.0% 3.4% 2.0% -0.7% -32.5% 35.6%
Quick Ratio 2.35
1.66
1.53
0.95
0.99
0.81
1.01
0.96
0.88
0.62
0.85
growth rate -29.4% -7.8% -37.9% 4.2% -18.2% 24.7% -5.0% -8.3% -29.6% 37.1%
Leverage 1.69
1.37
1.35
1.53
2.20
3.28
4.83
5.46
4.96
8.28
13.81
growth rate -18.9% -1.5% 13.3% 43.8% 49.1% 47.3% 13.0% -9.2% 66.9% 66.8%
Balance Sheet Dec '06 Dec '07 Dec '08 Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16
Acct.Receivable 93.80
171.00
274.80
717.72
1,108.84
1,676.30
2,269.10
2,687.00
2,517.00
growth rate 82.3% 60.7% 161.2% 54.5% 51.2% 35.4% 18.4% -6.3%
Acct.Payable 41.60
37.40
699.98
1,240.01
327.00
2,565.70
4,293.00
3,499.00
growth rate -10.1% 332.6% 77.2% -73.6% 684.6% 67.3% -18.5%
Cur.Assets 470.00
456.20
1,020.20
1,357.51
2,777.45
3,885.90
4,131.70
5,507.00
5,077.00
growth rate -2.9% 123.6% 33.1% 104.6% 39.9% 6.3% 33.3% -7.8%
Total Assets 1,187.40
1,305.50
10,795.10
13,108.12
17,950.38
27,970.80
26,304.70
48,965.00
43,529.00
growth rate 10.0% 726.9% 21.4% 36.9% 55.8% -6.0% 86.2% -11.1%
Cash 199.60
68.10
394.30
164.11
916.09
600.30
322.60
597.00
542.00
growth rate -65.9% 479.0% -58.4% 458.2% -34.5% -46.3% 85.1% -9.2%
Inventory 16.70
27.90
229.60
355.21
531.26
221.80
889.20
1,257.00
1,061.00
growth rate 67.1% 722.9% 54.7% 49.6% -58.3% 300.9% 41.4% -15.6%
Cur.Liabilities 292.20
331.10
692.50
924.27
1,822.75
2,512.40
2,708.40
5,313.00
3,609.00
growth rate 13.3% 109.2% 33.5% 97.2% 37.8% 7.8% 96.2% -32.1%
Liabilities 983.90
934.30
5,884.00
9,178.29
14,232.98
22,852.10
21,025.30
43,055.00
40,377.00
growth rate -5.0% 529.8% 56.0% 55.1% 60.6% -8.0% 104.8% -6.2%
LT Debt 399.38
0.00
447.90
552.10
3,574.50
6,539.76
10,535.44
17,162.90
15,228.00
30,265.00
29,845.00
growth rate -100.0% 23.3% 547.4% 83.0% 61.1% 62.9% -11.3% 98.8% -1.4%
Equity 1,302.26
1,297.82
203.40
371.20
4,911.10
3,929.83
3,717.40
5,118.70
5,279.40
5,910.00
3,152.00
growth rate -0.3% -84.3% 82.5% 1,223.0% -20.0% -5.4% 37.7% 3.1% 11.9% -46.7%
Common Shares 160.00
161.00
160.00
159.00
196.00
326.00
305.00
321.00
342.00
342.00
347.00
growth rate 0.6% -0.6% -0.6% 23.3% 66.3% -6.4% 5.3% 6.5% 0.0% 1.5%
Cash Flow Statement Dec '06 Dec '07 Dec '08 Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16
Capital Expenditures 44.80
35.09
22.00
-20.90
1.80
58.52
107.60
115.30
292.00
235.00
235.00
growth rate -21.7% -37.3% -100.0% 100.0% 3,150.8% 83.9% 7.2% 153.3% -19.5% 0.0%
Cash Dividends 80.06
321.52
0.00
0.00
356.30
52.50
0.00
0.00
0.00
0.00
growth rate 301.6% -100.0% -85.3% -100.0%
Cash From OA 521.96
340.85
216.50
183.60
263.20
640.47
656.60
1,042.00
2,312.00
2,257.00
2,087.00
growth rate -34.7% -36.5% -15.2% 43.4% 143.3% 2.5% 58.7% 121.9% -2.4% -7.5%
FCF per Share 2.67
1.90
1.14
-1.31
1.26
0.53
1.56
2.07
3.96
6.01
5.20
growth rate -28.8% -40.0% -100.0% 100.0% -57.9% 194.3% 32.7% 91.3% 51.8% -13.5%
Sale Purchase of Stock -206.50
-202.40
-650.00
-257.70
-55.60
17.00
1,391.00
33.00
growth rate 0.0% 0.0% 0.0% 0.0% 100.0% 8,082.4% -97.6%
FCF 477.00
306.00
182.00
-208.00
246.00
291.00
475.00
857.00
1,824.00
1,897.00
1,796.00
growth rate -35.9% -40.5% -100.0% 100.0% 18.3% 63.2% 80.4% 112.8% 4.0% -5.3%
Income Statement Dec '06 Dec '07 Dec '08 Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16
Sales 1,070.00
842.82
657.00
830.50
1,181.20
2,427.45
3,480.40
5,769.60
8,206.00
10,447.00
9,674.00
growth rate -21.2% -22.1% 26.4% 42.2% 105.5% 43.4% 65.8% 42.2% 27.3% -7.4%
Op.Income -190.30
257.60
-110.10
122.72
-136.10
-863.70
2,001.00
1,527.00
-566.00
growth rate 100.0% -100.0% 100.0% -100.0% 0.0% 100.0% -23.7% -100.0%
IBT -156.30
199.30
-236.30
-18.00
-394.20
-1,314.50
1,054.00
-155.00
-2,435.00
growth rate 100.0% -100.0% 0.0% 0.0% 0.0% 100.0% -100.0% 0.0%
Net Income -23.70
263.70
-208.20
122.72
-136.10
-866.10
881.00
-292.00
-2,409.00
growth rate 100.0% -100.0% 100.0% -100.0% 0.0% 100.0% -100.0% 0.0%
EPS 1.32
1.22
1.25
1.11
-1.06
0.49
-0.38
-2.70
2.58
-0.85
-6.94
growth rate -7.6% 2.5% -11.2% -100.0% 100.0% -100.0% 0.0% 100.0% -100.0% 0.0%
Gross Profit 856.57
619.14
505.60
635.40
775.50
1,731.35
2,510.70
3,864.50
5,970.00
7,862.00
7,063.00
growth rate -27.7% -18.3% 25.7% 22.1% 123.3% 45.0% 53.9% 54.5% 31.7% -10.2%
R&D 87.00
44.00
157.60
65.69
79.10
156.80
246.00
334.00
421.00
growth rate -49.4% 258.2% -58.3% 20.4% 98.2% 56.9% 35.8% 26.1%

Quarterly Statements

Item Name Jun '16 Sep '16 Dec '16 Mar '17 Jun '17
Earnings BIT 95.60
-862.20
107.20
179.00
217.00
growth rate -100.0% 100.0% 67.0% 21.2%
Balance Sheet Jun '16 Sep '16 Dec '16 Mar '17 Jun '17
Acct.Receivable 2,732.50
2,708.40
2,517.00
2,097.00
2,096.00
growth rate -0.9% -7.1% -16.7% -0.1%
Acct.Payable 3,761.40
3,750.50
3,499.00
3,852.00
3,630.00
growth rate -0.3% -6.7% 10.1% -5.8%
Cur.Assets 5,818.40
5,673.80
5,077.00
5,333.00
5,992.00
growth rate -2.5% -10.5% 5.0% 12.4%
Total Assets 47,662.20
45,761.20
43,529.00
42,333.00
41,733.00
growth rate -4.0% -4.9% -2.8% -1.4%
Cash 852.40
658.50
542.00
1,210.00
2,025.00
growth rate -22.8% -17.7% 123.3% 67.4%
Inventory 1,336.70
1,300.10
1,061.00
1,111.00
1,084.00
growth rate -2.7% -18.4% 4.7% -2.4%
Cur.Liabilities 4,226.40
3,896.80
3,609.00
4,247.00
4,465.00
growth rate -7.8% -7.4% 17.7% 5.1%
Liabilities 42,366.30
41,593.90
40,377.00
38,440.00
37,802.00
growth rate -1.8% -2.9% -4.8% -1.7%
LT Debt 30,773.20
30,386.20
29,845.00
28,198.00
27,648.00
growth rate -1.3% -1.8% -5.5% -2.0%
Equity 5,295.90
4,167.30
3,152.00
3,893.00
3,931.00
growth rate -21.3% -24.4% 23.5% 1.0%
Common Shares 9,914.90
10,034.40
10,038.00
10,041.00
10,085.00
growth rate 1.2% 0.0% 0.0% 0.4%
Cash Flow Statement Jun '16 Sep '16 Dec '16 Mar '17 Jun '17
Capital Expenditures 66.30
53.10
53.90
38.00
37.00
growth rate -19.9% 1.5% -29.5% -2.6%
Cash Dividends
growth rate
Cash From OA 449.20
569.50
512.50
954.00
268.00
growth rate 26.8% -10.0% 86.2% -71.9%
Sale Purchase of Stock 0.70
32.10
-0.10
-9.00
9.00
growth rate 4,485.7% -100.0% 0.0% 100.0%
FCF 382.90
516.40
458.60
916.00
231.00
growth rate 34.9% -11.2% 99.7% -74.8%
Income Statement Jun '16 Sep '16 Dec '16 Mar '17 Jun '17
Sales 2,419.80
2,479.40
2,402.60
2,109.00
2,233.00
growth rate 2.5% -3.1% -12.2% 5.9%
Op.Income 80.70
-863.30
150.30
211.00
175.00
growth rate -100.0% 100.0% 40.4% -17.1%
IBT -376.50
-1,331.90
-360.10
-295.00
-242.00
growth rate 0.0% 0.0% 0.0% 0.0%
Net Income -302.00
-1,218.40
-514.60
628.00
-38.00
growth rate 0.0% 0.0% 100.0% -100.0%
EPS
growth rate
Gross Profit 1,762.10
1,821.70
1,737.30
1,513.00
1,587.00
growth rate 3.4% -4.6% -12.9% 4.9%
R&D 124.40
101.20
92.80
96.00
94.00
growth rate -18.7% -8.3% 3.5% -2.1%

Growth Grade & Financial Ratios

All financial ratios below are calculated based on latest annual statements available and present the most up to date snapshot of a company finances.

Growth Grade

Historical Growth Grade:

E (25.12)

YOY Growth Grade:

E (19.33)

Click on buttons above for detailed yearly growth rates.

Market Ratios

Profitability Ratios

Liquidity Ratios

Efficiency Ratios

Value Price

Current EPS is negative, therefore value price cannot be calculated.

PE and EPS

Historical Current Forward
PE -3.71 -3.71 3.47
EPS / Growth 61.4% -3.27 15.2%

Value Price & Investment Recovery Time

Read more about Stock2Own value price in Stock Market: Fundamental Analysis.

Equity Growth Rate: 1.0%

Estimates Pessimistic Moderate Optimistic My Numbers
Rate of Return 15.0%
MOS Price % 50 %
Future EPS Growth 1.0% 8.1% 8.1%
Future PE 0.01 2.31 6.57
Future EPS 0.00 0.00 0.00
Value Price
MOS %
0.00
-100.0%
0.00
-100.0%
0.00
-100.0%
MOS Price 0.00 0.00 0.00
IRT 99.00 99.00 99.00

Graham Number:

Current EPS is negative, therefore Graham Number cannot be calculated.
NOTE: The Graham Number applies only to certain types of stocks in combination with a number of other criteria.

Read more about Graham Number in Stock Market: Fundamental Analysis.

Price Chart

Access denied

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE.

Risk / Reward Ratios

Access denied

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE.